RxDoctor Payments Data

Molly Lloyd

Acute Care · Washington, DCNPI 1588091300

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 26.5% of the total. Among acute care clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,042in general payments, 2019–2025

Across 69 payments — averaging $29.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$542
  • Incyte Corporation$257
  • Novartis$198
  • Takeda Pharmaceuticals U.S.A., Inc.$172
  • E.r. Squibb & Sons, L.L.C.$106
  • AbbVie$99
  • plus $669 from 20 others

What the payments were for

  • Food & beverage$2,042100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,042 in reported general payments places this provider in the 90th percentile of 110 acute care providers in District of Columbia.

See all acute care providers in District of Columbia

Medicare billing

Part B allowed, 2024
$7,430
Medicare patients
23
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate34$468,270
XareltoRivaroxaban18$17,334
Posaconazole11$12,241
ValacyclovirValacyclovir Hcl57$3,340
Fluconazole14$1,192
Dexamethasone14$1,188
Mirtazapine34$424
Nystatin15$416
Acyclovir13$276
Montelukast Sodium11$177
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim26$165
Prednisone16$104
Duloxetine Hcl12$100
Pantoprazole Sodium16$96
Minocycline Hcl13$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$257$468,27034 claims
Johnson & JohnsonXarelto$542$17,33418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 acute care providers in District of Columbia.

Other acute care in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →